# Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

> **NCT04745559** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 26 (actual)

## Conditions studied

- Diffuse Large-Cell Lymphoma
- Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Transformed Follicular Lymphoma (TFL)
- High-grade B-cell Lymphoma (HGBCL)
- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** Pneumococcal conjugate vaccine (PCV13)
- **BIOLOGICAL:** CD19 targeted CAR T Cell Therapy

## Key facts

- **NCT ID:** NCT04745559
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-18
- **Primary completion:** 2025-07-31
- **Final completion:** 2027-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745559, "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04745559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*